Cytisine inhibits the anticonvulsant activity of phenytoin and lamotrigine in mice

被引:0
作者
Piotr Tutka
Tomasz Mróz
Jerzy Bednarski
Andrzej Styk
Jaromir Ognik
Jerzy Mosiewicz
Jarogniew Łuszczki
机构
[1] University of Rzeszów,Department of Pharmacology, Institute of Nursing and Health Sciences
[2] Medical University of Lublin,Department of Experimental and Clinical Pharmacology
[3] Medical University of Lublin,Department of Internal Medicine
[4] Medical University of Lublin,Department of Pathophysiology
[5] Institute of Agricultural Medicine,Department of Physiopathology
来源
Pharmacological Reports | 2013年 / 65卷
关键词
cytisine; epilepsy; lamotrigine; maximal electroshock; nicotinic receptors; phenytoin; smoking cessation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:195 / 200
页数:5
相关论文
共 69 条
[1]  
Caulfield MP(1983)Mediation of nicotine-induced convulsions by central nicotinic receptors of the ’C6’ type Neuropharmacology 22 347-351
[2]  
Higgins GA(2005)Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation J Med Chem 48 3474-3477
[3]  
Coe JW(1999)Pharmacological characterization of nicotine-induced seizures in mice J Pharmacol Exp Ther 291 1284-1291
[4]  
Brooks PR(2006)Cytisine for smoking cessation, a literature review and a meta-analysis Arch Intern Med 166 1553-1559
[5]  
Vetelino MG(1949)A simplified method of evaluating dose-effect experiments J Pharmacol Exp Ther 96 99-113
[6]  
Wirtz MC(2005)How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol Rep 57 782-786
[7]  
Arnold EP(2011)7-Nitroindazole, but not N Pharmacol Rep 63 169-175
[8]  
Huang J(1995)-nitro-L-arginine, enhances the anticonvulsant activity of pregabalin in the mouse maximal electroshock-induced seizure model Science 269 1692-1696
[9]  
Sands SB(1994)Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors Mol Pharmacol 45 142-149
[10]  
Damaj MI(2010)Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit Br J Pharmacol 160 334-345